|
|
1655 Roberts Boulevard N.W.
Kennesaw, GA 30144 USA
phone:(770) 419-3355
fax:770-426-0031
|
|
| Symbol |
CRY |
| Exchange |
NYSE |
| Founded |
1984 |
| Employees |
405 |
|
|
| www.cryolife.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Development of implantable biological devices, surgical adhesives, and biomaterials |
|
| Management |
| Steven G. Anderson, Chairman, President and Chief Executive Officer; Bruce G. Anderson, Vice President, U.S. Sales and Marketing; Jeffrey W. Burris, Esq., Vice President and General Counsel; Scott B. Capps, Vice President, Clinical Research; David M. Fronk, Vice President, regulatory Affairs and Quality Assurance |
| |
|
|
|
|
|
|
|
| Keywords |
| contemporary, implantable, adhesives, biomaterials, cardiac |
|
|
|
| Description |
|
CryoLife is a contemporary biological medical device company that, since its founding in 1984, has been focused on the development of implantable biological devices, surgical adhesives, and biomaterials for use in cardiac, vascular, and spinal reconstruction for patients of all ages. |
|
| Products / Services |
CryoLife's human tissue preservation service draws revenue through cardiac and vascular allograft tissue preservation. A substantial portion of CryoLife's R&D efforts are focused on Protein Hydrogel Technologies, including BioFoam for severe wounds and the BioDisc for spinal repair. BioGlue is a biosurgical device which helps control bleeding in open surgical repair of large vessels.
|
|
| Technology / Differentiation |
| BioGlue is the first Protein Hydrogel Technologies product to be commercially introduced into world markets. BioGlue is a two-component surgical adhesive designed for cardiovascular, vascular, pulmonary, and general surgical applications. |
|
| Market / Customers |
Over 75% of all cardiovascular procedures involving allograft (homograft) tissue in the U.S. are performed with cryopreserved human heart valves from CryoLife. The company distributes its tissue to implantation institution is the U.S., Canada and Europe. BioGlue is used by surgeons to reinforce friable, diseased, or damaged tissues, such as cardiac and vascular tissue. CryoLife distributes BioGlue in more than 60 countries worldwide.
|
|
| Strategy |
Aurazyme Pharmaceuticals, a wholly owned subsidiary of CryoLife, is focusing on the development of novel drug therapies for cardiovascular and cancer treatment.
|
|
| Status |
| CryoLife's R&D efforts are focused on Protein Hydrogel Technologies (BioDisc for spinal repair and BioFoam for abdominal aortic aneurysms and severe wounds) and Antigen Reduction Technologies (bovine conduit for arteriovenous access). BioGlue is approved in the U.S. for use in adult patients as an adjunct to standard methods, such as sutures and staples. It is approved in the European Community and Canada as an adjunct to surgical repair for soft tissues. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members